Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
1.
Article de Anglais | WPRIM | ID: wpr-253602

RÉSUMÉ

<p><b>INTRODUCTION</b>Studies have suggested that women who present with non-ST-segment elevation myocardial infarction (NSTEMI) may differ in their clinical response to early invasive strategy compared to male patients. We examined the impact of gender difference in NSTEMI patients on outcomes following invasive versus conservative treatment.</p><p><b>MATERIALS AND METHODS</b>Patients enrolled in our national myocardial infarction (MI) registry between January 2000 and September 2005 with diagnosis of NSTEMI were retrospectively analysed. The study endpoint was the occurrence of major adverse cardiac events (MACE) in the patients at 1 year.</p><p><b>RESULTS</b>A total of 1353 patients (62.2% male) with NSTEMI were studied. The mean age of men was 62 +/- 14 versus 72 +/- 12 years in women in the cohort (P <0.001). The prevalence of hypertension and diabetes mellitus were significantly higher in women. Men were more likely to undergo revascularisation than women (OR, 2.97; 95% CI, 2.18-3.89, P <0.001). Among those who were revascularised, there was no gender difference in survival or recurrent MI rates during hospitalisation and at 1 year. Compared to medical therapy, percutaneous coronary intervention (PCI) was associated with a significant reduction in MACE in both women (OR, 0.44; 95% CI, 0.20-0.95) and men (OR, 0.40; 95% CI, 4.79-12.75). The most important predictor of MACE for females was diabetes mellitus (HR, 1.98; 95% CI, 1.17-3.33).</p><p><b>CONCLUSIONS</b>There is a gender-based difference in the rate of revascularisation among patients with NSTEMI. Women benefit from an invasive approach as much as men, despite their advanced age, with similar rates of mortality and recurrent MI at 1-year follow-up.</p>


Sujet(s)
Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Mâle , Adulte d'âge moyen , Antagonistes bêta-adrénergiques , Utilisations thérapeutiques , Angioplastie coronaire par ballonnet , Inhibiteurs de l'enzyme de conversion de l'angiotensine , Utilisations thérapeutiques , Électrocardiographie , Études de suivi , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase , Utilisations thérapeutiques , Infarctus du myocarde , Traitement médicamenteux , Chirurgie générale , Antiagrégants plaquettaires , Utilisations thérapeutiques , Types de pratiques des médecins , Récidive , Facteurs sexuels , Analyse de survie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE